Axon Enterprise, Inc. (NASDAQ:AXON) COO Sells $1,025,009.44 in Stock

Axon Enterprise, Inc. (NASDAQ:AXONGet Rating) COO Joshua Isner sold 5,537 shares of Axon Enterprise stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $185.12, for a total value of $1,025,009.44. Following the sale, the chief operating officer now owns 235,764 shares in the company, valued at $43,644,631.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Joshua Isner also recently made the following trade(s):

  • On Wednesday, January 4th, Joshua Isner sold 2,965 shares of Axon Enterprise stock. The stock was sold at an average price of $168.24, for a total value of $498,831.60.
  • On Tuesday, December 27th, Joshua Isner sold 1,392 shares of Axon Enterprise stock. The stock was sold at an average price of $168.73, for a total value of $234,872.16.
  • On Tuesday, December 20th, Joshua Isner sold 2,219 shares of Axon Enterprise stock. The stock was sold at an average price of $167.20, for a total value of $371,016.80.
  • On Monday, December 5th, Joshua Isner sold 1,556 shares of Axon Enterprise stock. The stock was sold at an average price of $186.40, for a total value of $290,038.40.
  • On Thursday, December 1st, Joshua Isner sold 275 shares of Axon Enterprise stock. The shares were sold at an average price of $177.96, for a total value of $48,939.00.

Axon Enterprise Stock Up 1.0 %

Shares of NASDAQ AXON opened at $184.06 on Friday. Axon Enterprise, Inc. has a 12 month low of $82.49 and a 12 month high of $193.85. The company has a current ratio of 2.79, a quick ratio of 2.39 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $13.10 billion, a price-to-earnings ratio of 126.94 and a beta of 0.79. The business has a 50-day moving average of $177.40 and a 200-day moving average of $144.65.

Axon Enterprise (NASDAQ:AXONGet Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.06 by $0.24. Axon Enterprise had a return on equity of 9.88% and a net margin of 9.75%. The company had revenue of $311.75 million during the quarter, compared to analyst estimates of $276.99 million. Sell-side analysts expect that Axon Enterprise, Inc. will post 0.54 earnings per share for the current fiscal year.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently bought and sold shares of AXON. American Century Companies Inc. boosted its stake in Axon Enterprise by 103.8% in the first quarter. American Century Companies Inc. now owns 6,194 shares of the biotechnology company’s stock worth $853,000 after buying an additional 3,155 shares in the last quarter. Private Advisor Group LLC lifted its position in Axon Enterprise by 40.3% in the first quarter. Private Advisor Group LLC now owns 3,458 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 994 shares during the last quarter. Great West Life Assurance Co. Can lifted its position in Axon Enterprise by 12.3% in the first quarter. Great West Life Assurance Co. Can now owns 37,062 shares of the biotechnology company’s stock valued at $5,247,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Trust N.A. lifted its position in Axon Enterprise by 4.7% in the first quarter. Raymond James Trust N.A. now owns 3,753 shares of the biotechnology company’s stock valued at $517,000 after purchasing an additional 168 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Axon Enterprise by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 236,287 shares of the biotechnology company’s stock valued at $32,545,000 after purchasing an additional 4,897 shares during the last quarter. Hedge funds and other institutional investors own 75.62% of the company’s stock.

Analysts Set New Price Targets

AXON has been the topic of a number of research reports. Robert W. Baird boosted their price objective on Axon Enterprise from $170.00 to $200.00 in a research note on Thursday, December 15th. Credit Suisse Group boosted their price objective on Axon Enterprise from $152.00 to $200.00 and gave the company an “outperform” rating in a research note on Tuesday, January 10th. Northland Securities boosted their price objective on Axon Enterprise from $140.00 to $160.00 in a research note on Wednesday, November 9th. StockNews.com assumed coverage on Axon Enterprise in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. Finally, Morgan Stanley upped their price target on Axon Enterprise from $130.00 to $155.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 13th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $181.13.

About Axon Enterprise

(Get Rating)

Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.

Further Reading

Insider Buying and Selling by Quarter for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.